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ABSTRACT
Background: Reported off-label/unlicensed
prescribing rates in children range from 11% to 80%.
Research into pharmacokinetic profiles of children’s
medicines is essential in the creation of more
knowledge on the safety and efficacy of medicines in
children. This study investigated how often
pharmacokinetic data are collected in clinical trials of
medicines in children by analysing registered records
of clinical trials.
Methods: The registered records of all clinical trials in
children that were recruiting on 22 May 2009 were
identified on the International Clinical Trials Registry
Platform using a Clinical Trials in Children search filter.
The records of trials in children below 12 years of age,
in which the intervention was one or more medicines,
were assessed for evidence that pharmacokinetic data
would be collected.
Results: Of 1081 eligible trial records, 257 (24%)
declared that pharmacokinetic data would be collected.
Of these trials, 199 (77%) recruited in Northern
America; recruitment in all other regions was below
20%. Trials recruited most often in children over
2 years of age (74%), and least often in newborn
infants (32%). Most trials researched medicines in the
field of cancer (29%). Trials investigated one-third of
the medicines that were indicated as a priority for
pharmacokinetic research by the European Medicines
Agency.
Conclusions: There is a need for increased knowledge
of the pharmacokinetic profiles of children’s
medicines. The amount of currently ongoing
pharmacokinetic research does not seem to address
adequately the lack of knowledge in this area. This
study sets a baseline for monitoring of future progress
on the amount of ongoing pharmacokinetic research in
children.
INTRODUCTION
Knowledge on the efficacy and safety of
medicines for children is still very limited.
Off-label (outside the product licence) and
unlicensed (without a licence for children)
prescription rates in children range from
11% to 80%.1 Only 20e30% of drugs that
have been approved by the US Food and
Drug Administration in the past were also
labelled for use in children.2 Adult dosing
cannot be logically extrapolated to paediatric
dosing according to weight or age because
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ARTICLE SUMMARY
Article focus
- The main aim of this study was to assess how
many registered records of clinical trials of
medicines that were recruiting children and
were identifiable on the International Clinical
Trials Registry Platform Search Portal contained
evidence that pharmacokinetic data would be
collected.
- Secondary aims were to assess which pharma-
cokinetic data were collected and what types of
trials were reporting pharmacokinetic data.
Key messages
- This study quantifies, for the first time, the
amount of currently ongoing research into
pharmacokinetic profiles of medicines in children.
- It shows how much and what kind of pharma-
cokinetic research is being carried out worldwide
as registered at clinical trial registries and
analyses the types of trials that perform this
research.
- It sets a baseline for future studies, to monitor
progress in the amount of pharmacokinetic
research that is performed in children.
Strengths and limitations of this study
- Our study is one of the first studies of its kind, in
that it has created a comprehensive oversight of
the amount of ongoing research in one particular
research area, by analysing information in regis-
tered records of clinical trials. Using information in
clinical trial databases as such offers a unique, and
currently underused, method for informing future
research prioritisation efforts at a policy level (in
our case of paediatric off-patent medicines by the
European Medicines Agency).
- This study is limited by the quality of information
in the included registered records. Studying
registered records of clinical trials is not the
same as studying how clinical trials were in fact
conducted. However, in the absence of open
access to complete trial protocols we have no
other choice than to use the information entered
into a trial registry for this type of analysis.
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of different pharmacokinetic and pharmacodynamic
profiles in children as compared with adults.3e5 Differ-
ences in drug metabolism between children and adults
also lead to differences in susceptibility to adverse drug
reactions.6 Worryingly, adverse drug reactions have been
shown to occur more frequently with off-label prescribed
drugs.7 The magnitude of this problem is exemplified by
one source which estimates that almost one-quarter of all
children in the USA used at least one prescription drug
in the last month and that the total number of drugs
used per 100 children in the USA over 2004 and 2005
was 338.4.8 To accelerate progress towards improved
availability and access to safe child-specific medicines for
all children below 12 years of age, the ‘Make medicines
child size’ campaign was launched by the WHO in 2007.9
It has been a requirement of the International
Committee of Medical Journal Editors since 2004 that all
clinical trials be prospectively registered in a publicly
available clinical trials registry in order to be considered
for publication of trial results.10 As of April 2011 the
WHO International Clinical Trials Registry Platform
(ICTRP) offers a single point of access (the ICTRP
Search Portal) to data from over 130 000 clinical trials
made available by clinical trial registries around the
world.11 The importance of high-quality information on
clinical trials recruiting children is increasingly being
recognised. The Pan African Clinical Trials Registry
(a WHO Primary Registry to the ICTRP) has, for
example, recently created a child strategy,12 and the
European Union has implemented legislation
mandating that the EudraCT database of clinical trials
‘should include a European register of clinical trials of
medicinal products for paediatric use’.13 To improve
access to information on clinical trials in children for
healthcare workers, researchers, and patients and their
parents, the ICTRP has developed a filter (referred to as
the Clinical Trials in Children or CTC filter) on the
ICTRP Search Portal which makes it possible to search
the portal for clinical trials in children with reasonable
accuracy.14
Collecting pharmacokinetic data in paediatric drug
trials is fundamental in the development of a larger body
of evidence on the safety and efficacy of children’s
medicines. The aim of this study was to assess how
many registered records of clinical trials of medicines
that were recruiting children and were identifiable
on the ICTRP Search Portal contained evidence that
pharmacokinetic data would be collected.
METHODS
Data sources
The ICTRP Search Portal imports the WHO Trial
Registration Data Set (the minimum amount of trial
information that must appear in a register in order for
a given trial to be considered fully registered) from
registries that meet WHO criteria, including Clin-
icalTrials.gov.15 As the format of each data item differs
across registries, data are currently imported into the
portal as text. The ICTRP publishes a hyperlink to the
record in the source registry (ie, the registry that
provided the data) so users can view additional infor-
mation, if required. At the time of this study, nine
registries provided data to the ICTRP: The Australian
New Zealand Clinical Trials Registry (ANZCTR), the
Chinese Clinical Trial Register (ChiCTR), the Clinical
Trials RegistrydIndia (CTRI), ClinicalTrials.gov, the
German Clinical Trials Register (DRKS), the Iranian
Registry of Clinical Trials (IRCT), the International
Standard Randomized Controlled Trial Number Register
(ISRCTN), the Netherlands National Trial Register
(NTR) and the Sri Lanka Clinical Trials Registry
(SLCTR).
During this study, the CTC filter operated through
a search paradigm of over 4000 keywords that were
compiled by consulting child-health experts who iden-
tified key terms relevant to children and adolescents.14
Study selection
The ICTRP database was searched for all recruiting,
interventional clinical trials in children using the CTC
filter. The resulting records were scanned manually for
eligibility. To be eligible, trial records needed to describe
trials that included children below 12 years of age. For
trials where inclusion of participants below 12 years was
unclear from the record, the record was considered
eligible only when an explicit statement was present that
the trial was recruiting children, or when the investi-
gated disease was listed as child-specific in the CTC
search-filter keyword database. When a trial researched
an intervention in pregnant mothers, records were only
included when outcomes were defined for the child.
Eligible trials also needed to have at least one arm that
involved the evaluation of one or more medicines.
Interventions were coded to be medicines or not by
using the coding system for intervention types on Clin-
icalTrials.gov.16 Interventions that were drugs, biologi-
cals or dietary supplements were considered to be
medicines. Excluded were records of trials that
researched general dietary interventions (as opposed to
dietary supplements), vaccines, intravenous fluids
(without mentioning of specific substance names),
oxygen and nitric or nitrous oxide treatments,
transplantations or transfusions, sucrose and glucose
water for treatment of pain in newborns, alcohol
cleansing of intravenous materials, somatic cell trans-
plants and transfusions, pro- and prebiotics, and
surfactant treatments.
Data extraction
The following information was collected manually for all
eligible registered records: the age of included partici-
pants, country/countries of recruitment, study phase
and nature of sponsorship. Geographical regions of the
United Nations Statistics Division were used to group
countries.17 The age of participants was categorised
according to the International Conference on
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Harmonisation topic E11 age classification of paediatric
patients.18
Eligible registered records were searched for the
presence or absence of collection of pharmacokinetic
data. Pharmacokinetic data were defined as parameters
that describe the fate of externally administered
substances to humans after administration. Both
parameters of the drug and its metabolites were denoted
to be pharmacokinetic data (eg, 25(OH)D or 1,25
(OH)2D levels were recorded as pharmacokinetic
outcomes of vitamin D treatment). Collection of phar-
macokinetic data could be mentioned in the outcome
entry fields or elsewhere in the record.
We determined whether pharmacokinetics were
recorded as a primary or a secondary outcome measure.
(If collection of pharmacokinetic data was mentioned
outside the outcome fields, it was denoted a secondary
outcome measure.) Furthermore, we documented which
of the following pharmacokinetic data were studied:
absorption, area under the curve of plasma or tissue
concentration, autoinduction response, balance, bioavail-
ability, breakdown, clearance, distribution, elimination,
excretion, faecal clearance, faecal excretion, lowest
concentration, metabolism, peak concentration, plasma
half-life (t1/2), plasma or tissue concentration, renal
clearance, time to lowest concentration, time to peak
concentration, urinary excretion, volume of distribution,
or general mentioning of pharmacokinetic data collection
or a pharmacokinetic study design. Use of a population
pharmacokinetic design and additional general
mentioning of pharmacodynamic data collection or the
use of a pharmacodynamic study design were denoted.
The primary health condition or problem studied and
the drug, biological or dietary supplement that was
under investigation were denoted for trials that reported
collection of pharmacokinetic data. The primary health
condition or problem studied was categorised according
to WHO Tenth Revision of the International Classifica-
tion of Diseases chapters.19 For drugs, biologicals and
dietary supplements, we adhered to the names for the
interventions as denoted in the registered record, except
when proprietary names were used, which we converted
to non-proprietary names. When there were multiple
medicines described, but there was one main interven-
tion, and the record lacked specification for which
medicines pharmacokinetics would be determined, it
was assumed that pharmacokinetics would be deter-
mined for the main intervention. The drugs, biologicals
and dietary supplements that were found were
compared with the medicines for which there was
a priority need for pharmacokinetic data, according to
the European Medicines Agency (EMA) revised priority
list for studies into off-patent paediatric medicinal
products from 2008, which was the most recent version
at the time of this study.20 Furthermore, we analysed the
EMA 2009 and 2010 priority lists to see whether
medicines from the 2008 list endured to be priorities for
pharmacokinetic investigation. Lastly, to investigate
whether there were any trials that studied EMA priority
medicines without collecting pharmacokinetic data, we
searched the scientific and public titles of all studies in
our sample for mention of the EMA priority medicines.
All records were scanned for eligibility by RFV who
then, in case of inclusion, extracted and coded the data.
During eligibility assessment and data extraction, trial
records for which data were ambiguous were further
assessed by DG. Conflicts were resolved by mutual
agreement.
SPSS V. 16.0.1 was used for descriptive analyses of the
data.
RESULTS
The ICTRP Search Portal was searched using the CTC
filter on 22 May 2009 resulting in the identification of
3051 records of interventional clinical trials in children,
of which 1081 were investigating one or more medicines
(ie, the intervention was a drug, biological or dietary
supplement) and mentioned inclusion of children below
12 years of age. Two hundred and fifty-seven (24%) of
these records reported that pharmacokinetic data would
be collected. The medicines that were investigated by the
corresponding trials were drugs or biologicals in 209
records (81%) and dietary supplements in 48 records
(19%).
The 1081 records of children’s trials reported
recruitment of participants in 92 countries; the records
that reported collection of pharmacokinetic data
recruited in 48 countries. Of the 257 records that
reported collection of pharmacokinetic data, 199
records (77%) reported recruitment in Northern
America; recruitment in all other regions was below 20%
(table 1). Among the 824 records of trials without
pharmacokinetic data collection, Northern America
was also the most frequent geographical region of
recruitment, but less so (57%).
Looking more closely at the age of participants being
recruited in trials that reported collection of pharma-
cokinetic data, 81 records (32%) involved preterm or
term newborn infants (0 to 27 days), 126 records (49%)
infants and toddlers (28 days to 23 months) and 190
records (74%) children between the ages of 2 and
11 years.
Mention of pharmacokinetic data collection was most
frequent in records of trials that were Phase 1 (62%) or
Phase 1 and 2 (57%). Thirty-nine per cent of all trials
that reported pharmacokinetic data collection were
Phase 1 or Phase 1 and 2, and 43% were Phase 2 to 4
(in 19% of records, the study phase was not provided).
Almost half of the trials that were reported to collect
pharmacokinetic data were sponsored by a university or
a hospital. Although there were fewer federal-sponsored
(15%) and industry-sponsored (26%) trials performing
research into medicines in children under 12 years,
these trials were more likely to collect pharmacokinetic
data (32% and 37% respectively) than university- or
hospital-sponsored studies (19%).
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Of the 257 records that reported collection of phar-
macokinetic data, 56 records (22%) mentioned only the
measuring of serum or tissue concentrations and did not
mention a pharmacokinetic study design, or any of the
other pharmacokinetic parameters (34 of these 56
records (61%) were of trials that investigated dietary
supplements). Figure 1 shows in more detail which
pharmacokinetic data were reported to be collected
in records. One hundred and twenty-four records
(48%) reported pharmacokinetic data as a primary
outcome, and 163 (63%) reported pharmacokinetic
data as a secondary outcome (the overlap is due to the
mention of pharmacokinetic data as both a primary
and a secondary outcome measure in 30 records).
Eleven records (4%) mentioned use of a population
pharmacokinetic design. Fifty-two records (20%)
mentioned pharmacodynamic data collection or the use
of a pharmacodynamic study design in addition to
pharmacokinetic data collection (out of the 824 records
that did not report pharmacokinetic data collection, 12
records mentioned collection of pharmacodynamic
data).
The primary health condition or problem studied in
trials that collected pharmacokinetic data was most often
Table 1 Age groups of study participants, geographical regions of recruitment, study phase and sponsorship of trial records
included in the study
Records from trials that
reported collection of
pharmacokinetic data
(N[257)
Records from trials that
did not report collection
of pharmacokinetic
data (N[824)
Total
Percentage of total
reporting collection
of pharmacokinetic
data per age group,
region, phase or
sponsor
No of
records
Percentage
of N[257
No of
records
Percentage
of N[824
Age*
Newborn infants
(0 to 27 days)
81 32 226 27 307 26
Infants and toddlers
(28 days to 23 months)
126 49 371 45 497 25
Children between the
ages of 2 and 11 years
190 74 680 83 870 22
Not indicated 3 1 19 2 22 e
Geographical region*
Africa 16 6 44 5 60 27
Asia 26 10 94 11 120 22
Europe 50 19 217 26 267 19
Latin America and
the Caribbean
25 10 61 7 86 29
Northern America 199 77 469 57 668 30
Oceania 13 5 83 10 96 14
Not specified 12 5 35 4 47 e
Phase
0 0 0 3 0 3 0
1 69 27 43 5 112 62
1 and 2 31 12 23 3 54 57
2 45 18 149 18 194 23
2 and 3 11 4 32 4 43 26
3 38 15 215 26 253 15
3 and 4 0 0 4 0 4 0
4 15 6 146 18 161 9
Not indicated 48 19 209 25 257 e
Sponsorship
Collaborative research
groups
25 10 80 10 105 24
Federal 39 15 84 10 123 32
Industry 67 26 114 14 181 37
University or hospital 121 47 502 61 623 19
Othery 5 2 43 5 48 10
Not indicated 0 0 1 0 1 e
Total 257 824 1081
*Percentages for geographical regions and age groups do not add up to 100% because records regularly pertain to trials recruiting in multiple
regions, or recruiting in multiple age groups.
yOther sponsorship included foundations, contract research organisations, research centres and individuals.
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cancer (29%) (figure 2). The distribution of health
conditions or problems studied differed per age group,
with less of a propensity for cancer research among the
group of newborn infants (figure 3).
A detailed oversight of the medicines that were inves-
tigated by trials that reported collection of pharmacoki-
netic data can be found in Web Only File 1. Of the
28 medicines on the EMA revised priority list for studies
into off-patent paediatric medicinal products from 2008
for which collection of pharmacokinetic data was
indicated to be a priority, we found nine medicines
(32%) to be investigated in trials identified in our search
(table 2).
Of the 28 medicines that were EMA priorities in 2008,
14 (50%) were still a priority in 2009 and 12 still in 2010
(43%). Of the nine medicines for which we found
pharmacokinetic data collection, two were still a priority
in 2010 (22%). Of the 19 medicines for which we did not
find pharmacokinetic data collection, 10 were still
a priority in 2010 (53%).
Academic and public titles of the 1081 records in the
sample were searched for the names of the 19 medicines
for which we did not find pharmacokinetic data collec-
tion in any record. Eight (42%) of these medicines were
identified in 29 trial records as an intervention.
DISCUSSION
To our knowledge, this is the first study to report on the
global activity of collection of pharmacokinetic data in
clinical trials in children. It assessed all paediatric trials
that were recruiting on 22 May 2009, as registered at
clinical trial registries that are a part of the ICTRP
registry network. Of 1081 records of trials researching
medicines in children, one-quarter reported that they
would be collecting pharmacokinetic data. So, is this
a lot or a little? In view of the current paucity of knowl-
edge on safety and efficacy of children’s medicines, the
degree to which this knowledge is in arrears as compared
with our understanding of adult medication, and the
widespread prescribing of medicines to children, we
would argue that it is not enough.
The fact that only one-fifth of the records that
mentioned collection of pharmacokinetic data also
mentioned studying pharmacodynamics adds to this
conclusion. Additionally, our analysis of the types of
trials researching pharmacokinetics shows that there
might be significant pharmacokinetic research gaps in
terms of geographical area, studied diseases and age
categories. Over 75% of all studies recruited participants
in Northern America, while recruitment in all other
geographical regions was below 20%. This unequal
distribution appears to exist for all paediatric drug
trials, but especially for studies collecting pharmacoki-
netic data. Given the existence of interethnic
differences in pharmacological effects on the body21 and
that many diseases are not prevalent in Northern
America, this gap is a reason for concern. Similarly, the
distribution of pharmacokinetic research across
Figure 1 Collected
pharmacokinetic (PK) data in
paediatric drug trials. Every first
bar represents which
pharmacokinetic data were
reported as a primary outcome;
every second bar those that were
reported as a secondary outcome.
AUC, area under the curve.
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different disease categories suggests that the lack of
knowledge of pharmacokinetics in children is only
marginally addressed in some areas. Previous studies
have shown that paediatric research in general often
does not address priority research areas.22 23 Finally,
although knowledge on pharmacokinetic profiles in
children is at an inadequate level for all age groups, least
is known about pharmacokinetics in the youngest age
group of neonates.24 25 This study shows that this age
group, worryingly, is also the least likely to be studied.
In addition, trials in our study sample were found to
collect pharmacokinetic data only for one-third of the
medicines on the EMA priority list for studies into off-
patent paediatric medicinal products.20 Although our
study investigated a cross-sectional sample of recruiting
paediatric trials at one moment in time, one-third seems
to be a low percentage. Also taking into consideration
that a considerable amount of medicines endured to be
priorities for research over several years, and that there
were ongoing clinical trials in which the pharmacoki-
netic properties of these medicines could potentially
have been studied, this might suggest that more research
on pharmacokinetic profiles in children is not only
necessary but also achievable.
The paediatric research community has much to gain
from the inclusive database of clinical trials in children
that the ICTRP search portal provides through its Clin-
ical Trials in Children search filter.26 Clinical trials
registration allows for doctors and patients and their
parents to inform themselves more adequately about
trials open to recruitment.27 It is likely to promote
collaboration among researchers, by facilitating knowl-
edge transfer on currently ongoing research, thus also
preventing duplication of research.28 Furthermore, it
has the potential to contribute to establishing more
reliable research evidence by aiding in the prevention
of selective reporting and publication bias.27 29
Although the ethical and legal pressure to adequately
report the results of clinical trials is increasing,30 selec-
tive reporting and publication bias are still important
problems.31 32 If all trials (and their outcomes) are
registered before the start of the trial, researchers who
withhold publication of trial results or the original
outcomes because of negative results can be held
accountable.30 33 34 Finally, clinical trials registration
facilitates priority setting in paediatric research, identi-
fying gaps between burden of disease and research efforts
in different therapeutic areas.35 This study confirms that
analysis of clinical trials identified in the ICTRP database
can be a powerful tool to comprehensively assess the
amount of currently ongoing research in a particular
research area.
Figure 2 Investigated health conditions or problems in trials that collected pharmacokinetic data. ICD-10, Tenth Revision of the
International Classification of Diseases.
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Figure 3 Investigated health conditions or problems per age group. The graph on the top left displays the distribution of health
conditions or problems studied in trials that recruited only newborn infants; the top-right graph displays this information for trials that
recruited only infants/toddlers; the middle left graph for trials that recruited only children >2 years of age; the middle right graph for
trials that recruited newborn infants and infants/toddlers; the lower left graph for trials that recruited infants/toddlers and children
>2 years of age; and the lower right graph for trials that recruited newborn infants, infants/toddlers and children >2 years of age.
ICD-10, Tenth Revision of the International Classification of Diseases.
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The need for improved availability of and access to
safe child-size medicines has received growing attention
in recent years.1 36 WHO addresses this issue through its
‘make medicines child size’ campaign.9 Other initiatives
that promote trials on medicines in children include US
and EU legislation.13 37 While these legislative measures
are a positive development and have resulted in an
increased number of trials being conducted in the
paediatric population,37 38 they have not been free from
critique.23 39 Given how crucial pharmacokinetic
research is in the creation of more knowledge on the
safety and efficacy of medicines in children and the
Table 2 European Medicines Agency (EMA) 2008 priorities for pharmacokinetic (PK) analysis
Name of medicine Notes
Investigated in
trial records
identified on the
International
Clinical Trials
Registry Platform
search portal?
Still in
2009
EMA
priorities?
Still in
2010
EMA
priorities?
Medicine
investigated
in trials
without
collection
of PK data?
In how
many trial
records?
6-Mercaptopurine In infants Yes Yes No
Actinomycin Below the age
of 6 years
Yes No No
Asparaginase In infants Yes No No
Baclofen Yes No No
Bumetanide No No No No
Carboplatin Below the
age of 3 years
No No No Yes 10
Cladribine No No No No
Clindamycin No Yes Yes No
Clonidine No Yes Yes Yes 6
Cyclophosphamide Data on PK
of metabolites
Yes, including
metabolites
No No
Cytarabine In infants Yes Yes No
Daunorubicin In infants Yes Yes Yes
Ethosuximide No Yes Yes No
Foscarnet No No No No
Glibenclamide Above 6 years
and adolescent
No Yes Yes No
Hydrochlorothiazide No No No No
Ibuprofen Parenteral formulation No* Yes Yes Yes 1
Itraconazole No Yes Yes No
Levamisole No No No No
Meropenem Below 3 months
of age
No No No No
Metformin In children above 6 years
with DM II and in small-
for-gestational-age children
with precocious/early/rapidly
progressing puberty
No Yes Yes Yes 2
Midazolam No No No Yes 4
Milrinone No Yes Yes Yes 2
Oxybutynin No No No No
Propranolol No Yes Yes Yes 2
Temozolomide In children particularly
below the age
of 3 years
Yes No No
Topotecan Yes Yes Yes
Unfractionated heparin No Yes Yes Yes 2
Percentage ‘Yes’ 9/28¼32% 14/
28¼50%
12/
28¼43%
8/19¼42%
This table shows which of the medicines that were identified as a priority for PK evaluation by the EMA in 2008 were found to collect PK data in
our study sample. We also assessed whether these medicines were still present in the EMA 2009 and 2010 priority lists. Lastly, we searched
titles of all 1081 trial records in our sample to assess for which EMA priority medicines trials were conducted without PK data collection (or it was
not denoted in the record).
*One trial investigated ibuprofen pharmacokinetics, but in oral formulation.
DM II, Diabetes mellitus type II.
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concerns that the present study raises on the amount of
such research currently being conducted, it is of great
importance that the collection of pharmacokinetic data
in clinical trials in children continues to be monitored in
the future. The Clinical Trials in Children search filter of
the ICTRP offers a platform to do so.
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